# Study of Single Dose GHB16L2 Trivalent Influenza Vaccine in Healthy Adults

> **NCT01369862** · PHASE1,PHASE2 · COMPLETED · sponsor: **AVIR Green Hills Biotechnology AG** · enrollment: 80 (estimated)

## Conditions studied

- Influenza, Human

## Interventions

- **BIOLOGICAL:** GHB16L2
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT01369862
- **Lead sponsor:** AVIR Green Hills Biotechnology AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2014-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01369862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01369862, "Study of Single Dose GHB16L2 Trivalent Influenza Vaccine in Healthy Adults". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01369862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*